OKYO Pharma Limited (“OKYO” or the “Company”) Announces the First Drug Candidate of its OK-101 Class Showing Both Anti-inflammatory and Eye Pain Reduction Potential for the Treatment of Dry Eye

LONDON, Dec. 13 2021 (GLOBE NEWSWIRE) – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of new molecules to treat inflammatory dry eye (SED) and eye pain, has the Pleased to announce that its drug candidate OK-101, which was developed to treat DED through its anti-inflammatory mode of action, also exhibits a potent eye pain reduction property determined using a mouse model of corneal neuropathic pain, establishing the potential to treat both pain and inflammation, the most common symptoms of dry eye, with a single drug.

In collaboration with Pedram Hamrah, MD, Acting President of Ophthalmology, Cornea Specialist and Clinician Scientist at Tufts Medical Center, Boston, OK-101 has been shown to suppress corneal pain in a mouse model of ciliary nerve ligation of neuropathic corneal pain developed in Dr. Hamrah’s laboratory. OK-101 was administered topically to mice compared to the positive control gabapentin which was administered by intraperitoneal injection. Pain relief was assessed by a number of eye wipes, and OK-101 has been shown to reduce corneal pain similar to that of gabapentin, an oral medicine commonly used for neuropathic pain. Notably, the concentration of drug OK-101 used in this study was identical to that used in mouse models of DED which demonstrated ocular anti-inflammatory activity.

“Eye pain, which can manifest as a serious, chronic, or debilitating condition in patients with many ophthalmic conditions, is currently being treated with various topical and systemic treatments in an inconsistent manner,” said Dr. Hamrah. “However, no approved commercial treatment is currently available for this disease, and we are excited about these positive results with OK-101 in our neuropathic corneal pain model of this disease.”

“The pain relief potential of a dry eye drug is very important because a considerable number of dry eye patients with chronic inflammation experience eye pain and a burning and granulation sensation,” said Raj Patil, PhD, Scientific Director of OKYO. “The discovery of the pain-reducing function of OK-101, in addition to its known anti-inflammatory activity, offers the possibility that our drug could potentially relieve pain in addition to reducing eye inflammation in millions of people. patients with DED. “

“We are currently focused on completing pre-IND work on OK-101 and plan to file IND on OK-101 to treat DED in the third quarter of 2022, followed by the start of a phase 2 trial in patients. with DED in the fourth quarter of 2022, ”said Dr. Gary S. Jacob, CEO of OKYO. “The recent discovery that OK-101 has both anti-inflammatory and ocular pain-relieving activity is an exciting development, and we believe that OK-101 may provide a novel way to treat DED patients who are currently not well. used by drugs currently approved to treat dry eye.

The person who arranged for the publication of this announcement on behalf of the Company was Gary S. Jacob, Ph.D., CEO of OKYO.

THIS AD CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596 / EU WHICH IS PART OF THE NATIONAL LAW OF THE UNITED KINGDOM IN ACCORDANCE WITH THE MARKET ABUSE REGULATION (AMENDMENT) (EU RELEASE) (SI 2019 / 310) (“UK MAR”). UPON THE PUBLICATION OF THIS AD, SUCH INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Surveys:

OKYO Pharma Limited

Gary S. Jacob, Chief Executive Officer

Gabriele Cerrone, Non-Executive Chairman

+44 (0) 20 7495 2379

Optiva Securities Limited
(Broker)

Robert emmet

+44 (0) 20 3981 4173

RedChip Companies Inc.
(Investor Relations)

Dave gentry

[email protected]

+1 407-491-4498

Notes to Editors:

About OK-101

OK-101 is a novel long-acting G protein coupled receptor-based lipidated chimera peptide developed to bind to ChemR23 receptors commonly found on immunological cells present in the eye. ChemR23 plays an important role in the inflammatory response, and binding of OK-101 to ChemR23 has been shown to produce anti-inflammatory activity in mouse models of SSO. OK-101 was developed using membrane-anchored peptide (MAP) technology to produce a long-acting drug candidate designed to combat leaching through the inclusion of an ‘anchor »Lipid in its molecular structure to improve the residence time on the ocular surface.

About Dr Hamrah

Dr Hamrah is Acting Chairman of the Department of Ophthalmology at Tufts Medical Center, clinician / scientist and prominent KOL in the field of dry eye, eye pain and eye immunology. He has received numerous awards, including the Senior Achievement Award from the American Academy of Ophthalmology, and is a Gold Fellow of the Association for Research in Vision and Ophthalmology. Professor Hamrah is currently Associate Editor of The Ocular Surface, Translational Vision, Science & Technology and Frontiers in Medicine (Ophthalmology), is Editor of the Eye Section, Associate Editor of the journal. ‘Ocular Immunology and Inflammation’ and is a member of several other editorial boards. He is the author of over 150 peer-reviewed articles, over 40 book reviews and chapters, and has given over 120 lectures and presentations worldwide.

About OKYO

OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) is a life sciences and biotechnology company admitted to the standard segment of the official list of the UK Financial Conduct Authority and to trading on the main securities market. listed on the London Stock Exchange. plc. OKYO is focused on the discovery and development of new molecules to treat inflammatory diseases of dry eye and eye pain.

About Dry Eye Disease (DED)

Dry eye is a multifactorial disease that causes eye discomfort and tear film instability which can lead to eye surface damage. It is often a chronic problem, especially among the elderly, and is expected to become even more prevalent with the aging of the population and the increased use of digital screens such as computers and smart phones. Despite the approval of new products, DED remains a significant unmet medical need and is a leading cause of patient visits to eye care specialists. New therapies that improve the signs and symptoms of dry eye will benefit patients with dry eye.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but are rather based on the Company’s current expectations, estimates and projections regarding its industry; his beliefs; and assumptions. Words such as “expect”, “expect”, “intend”, “plan”, “believe”, “seek”, “estimate” and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of the Company, are difficult to predict and could cause actual results differ materially from those expressed or expected. in forward-looking statements. The Company cautions securityholders and potential security holders not to place undue reliance on these forward-looking statements, which do not reflect the Company’s views until the date of this announcement. The forward-looking statements contained in this announcement relate only to events that occurred on the date on which the statements are made. The Company will not undertake any obligation to publicly post any revisions or updates to such forward-looking statements to reflect any unforeseen event, circumstance or event occurring after the date of such announcement, except as required by law or by any appropriate regulatory authority.

For more information, please visit the company’s website at www.okyopharma.com.


Source link

Back To Top